GSK blood cancer drug nearly halves risk of death in late-stage trial
- GSK's , opens new tab multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the incurable blood cancer, according to data from a late-stage study presented at a medical meeting on Sunday.
That compared with progression-free survival of 51% of those who were treated with pomalidomide, dexamethasone and bortezomib. Pomalidomide is a generic version of Bristol Myers Squibb's , opens new tab Pomalyst, while bortezomib is the generic of Takeda Pharmaceuticals' , opens new tab Velcade. Detailed data from the trial was presented at the American Society of Clinical Oncology meeting in Chicago on Sunday.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Moderna wins COVID shot patent case, Pfizer gets damages in cancer drug patent trialPfizer loses against Moderna, but remains winner against AstraZeneca
Baca lebih lajut »
Papua New Guinea: Landslide puts thousands life at risk as hopes for survivor’s fadePapua New Guinea authorities have warned nearly 7,900 people living near the site of a deadly landslide that they are 'at risk' as rock
Baca lebih lajut »
Pfizer lung cancer drug expected to top $1bn in sales following impressive five-year dataChina considered to be a particularly important market for Lorbrena
Baca lebih lajut »
New breast cancer genes found in women of African ancestry may improve risk assessmentSome of the mutations identified had not previously been linked with the disease
Baca lebih lajut »
Iraq father begins legal action against BP over son's cancer deathThe bereaved father is demanding that the firm compensate him for his son Ali's medical expenses
Baca lebih lajut »
Ranbir Kapoor smeared with blood, pictures go viralBlood-stained pictures of Bollywood actor Ranbir Kapoor have gone viral on social media.
Baca lebih lajut »